Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan.
Am J Surg Pathol. 2013 Jul;37(7):1030-8. doi: 10.1097/PAS.0b013e3182834d22.
Intraorgan metastasis of a primary cancer within the organ of origin, such as intrahepatic metastasis of hepatocellular carcinoma, is one of the key features for clinicopathologic staging of the cancer. Pancreatic intraglandular metastasis (P-IM) of pancreatic ductal carcinoma (PDC) is encountered occasionally but has not yet been evaluated. The aim of this study was to investigate the clinicopathologic characteristics and prognostic value of P-IM in patients with PDC. The histopathologic features of 393 consecutive patients with PDC who had undergone pancreatic resection at the National Cancer Center Hospital, Tokyo, between 2003 and 2010 were reviewed. For the purposes of the study, P-IM was defined as an independent tumor showing histopathologic features similar to those of the primary one. Twenty-six cases of P-IM were identified in 21 (5.3%) of the reviewed patients. The incidence of P-IM at each stage of the TNM classification was 0% (0/7) at stage IA, 17% (1/6) at stage IB, 5% (5/92) at stage IIA, 4% (11/252) at stage IIB, 0% (0/1) at stage III, and 11% (4/35) at stage IV. Univariate survival analysis showed that both overall survival and disease-free survival for patients with P-IM were significantly shorter than for those without P-IM (P<0.001 and P=0.019, respectively). Multivariate survival analysis showed that P-IM was significantly correlated with shorter overall survival (P=0.002; hazard ratio=2.239; 95% confidence interval: 1.328-3.773). Our findings suggest that the presence of P-IM in patients with PDC is an independent prognosticator and may represent aggressive tumor behavior.
原发肿瘤在器官内的转移,如肝细胞癌的肝内转移,是癌症临床病理分期的关键特征之一。胰腺导管腺癌(PDC)的胰腺内转移(P-IM)偶尔会遇到,但尚未得到评估。本研究旨在探讨 P-IM 在 PDC 患者中的临床病理特征和预后价值。回顾性分析了 2003 年至 2010 年在日本国家癌症中心医院接受胰腺切除术的 393 例连续 PDC 患者的组织病理学特征。为了进行本研究,将 P-IM 定义为具有与原发性肿瘤相似的组织病理学特征的独立肿瘤。在回顾的患者中,有 21 例(5.3%)患者发现了 26 例 P-IM。在 TNM 分期的每个分期,P-IM 的发生率为 IA 期为 0%(0/7),IB 期为 17%(1/6),IIA 期为 5%(5/92),IIB 期为 4%(11/252),III 期为 0%(0/1),IV 期为 11%(4/35)。单因素生存分析显示,P-IM 患者的总生存和无病生存均明显短于无 P-IM 患者(P<0.001 和 P=0.019)。多因素生存分析显示,P-IM 与总生存时间缩短显著相关(P=0.002;风险比=2.239;95%置信区间:1.328-3.773)。我们的研究结果表明,PDC 患者存在 P-IM 是独立的预后因素,可能代表肿瘤侵袭性行为。